not specific Archives - Page 2 of 3

Home
/
Projects
/

not specific

TB vaccine advocacy fellowship

2023

An urgent call for increased global investment and political support for TB vaccine R&D. With the United Nations High-Level Meeting on TB taking place on 22 September 2023, this call will play an important part in amplifying the voices of the global TB community in demanding new TB vaccines. This letter is also in direct support of the recently launched call to action ‘Deadly Divide: Priorities to Close the Deadly Divide’ from the Stop TB Partnership community and non-governmental organization delegations.

TB vaccine advocacy roadmap

2021

The TB Vax ARM represents a global coalition of TB stakeholders, including TB survivors, civil society organizations, and non-profits, invested in TB vaccine advocacy and research, and seeks to provide coordinated advocacy efforts that are complementary to ongoing TB vaccine R&D and policy efforts. The TB Vax ARM holds regular virtual calls with partners and guest speakers from around the world. WGNV coordinates with the TB Vax ARM on global advocacy activities. For more information go to: https://newtbvaccines.org/take-action/

Global plan to end tb

2023

Innovative Financing for TB vaccine R&D

2023

T20 policy brief

Lessons from a decade of adult vaccine rollout in low- and middle-income countries: A scoping review

2023

This paper synthesizes the insights and lessons learned from different vaccine introductions among adult populations in LMICs from the last decade (i.e., 2013 to 2023).

Accelerating access to novel TB vaccines

2024-2027

Hypothetical vaccines

Development of global early-stage, needs-based demand forecast for novel TB vaccines as input for the TB Vx Accelerator Finance and Access Working Group; identification of access barriers and problem solving for resultion

The full value of vaccine assessments concept—current opportunities and recommendations

2024

Building on the success of the recent applications of the FVVA framework, we see important new opportunities to maximize the future utility of FVVAs to country and global stakeholders and provide a proof-of-concept for analyses in other areas of disease control and prevention.

Mapping the existing body of knowledge on new and repurposed TB vaccine implementation: A scoping review

2024

BCG revaccination, Hypothetical vaccines, M72/AS01e

By synthesizing the existing body of knowledge, this review offers comprehensive insights into the current state of research on implementation of these TB adults and adolescent vaccines. Offering insights into key dimensions: (1) epidemiological impact, (2) costing, cost-effectiveness, and/or economic impact, (3) acceptability, and the (4) feasibility of implementation; this includes implementation strategies of target populations, and health system capabilities.

An investment case for new tuberculosis vaccines

2022

Hypothetical vaccines

This document summarizes the results of the WHO-commissioned full value proposition for new TB vaccines. It is for use by national and global decision-makers involved in vaccine development and implementation.

Evidence considerations for vaccine policy development for tuberculosis vaccines intended for adults and adolescents

2023

Hypothetical vaccines

The ECVP facilitates early engagement and alignment across the stakeholders involved in vaccine development and those responsible for vaccine regulatory, policy, funding and country introduction decisions. This framework aims to anticipate and collectively delineate the clinical trial, observational, and other data likely to be required by global and national policymakers, and to do so when most valuable – during development of the late-stage clinical plan, including the design of the pivotal licensure trial.